LAX.SH
NEULAND LAB LTD.·PHARMACEUTICALS 70.24CDMO 78.00·Pharmaceuticals & Biotechnology Companies
Price
23,301
-1.14%52W Range
Market Cap
₹29,894.92 Cr
Traded: ₹68.29 Cr (0.23%) 0.0x
Free Float: ₹7,171.79 Cr (0.95% of FF traded)
Volume · 60D trend
29.21 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | +14.0% | +18.0% | +20.0% | -- | -- | Accelerating |
| Return | +36.0% | +64.0% | +75.0% | +56.0% | -- | Stable |
| Profit | +29.0% | +39.0% | +30.0% | -- | +278.0% | Stable |
| Sales | +15.0% | +17.0% | +19.0% | -- | +78.0% | Accelerating |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 642 | 776 | 440 | 514 | 293 | 328 | 398 | 311 | 440 | 385 | 393 | 418 | 363 | 407 | 269 | 294 |
| Expenses | 419 | 469 | 363 | 359 | 258 | 277 | 311 | 249 | 316 | 278 | 272 | 280 | 266 | 287 | 215 | 224 |
| Operating Profit | 223 | 307 | 77 | 156 | 34 | 51 | 87 | 62 | 123 | 107 | 121 | 137 | 97 | 120 | 54 | 69 |
| OPM % | 35.0% | 40.0% | 18.0% | 30.0% | 12.0% | 16.0% | 22.0% | 20.0% | 28.0% | 28.0% | 31.0% | 33.0% | 27.0% | 29.0% | 20.0% | 24.0% |
| Other Income | 8 | 12 | 8 | 2 | 8 | 7 | 60 | 4 | 25 | 5 | 2 | 3 | 2 | 8 | 1 | 0 |
| Interest | 7 | 7 | 7 | 5 | 5 | 2 | 2 | 1 | 3 | 4 | 4 | 4 | 2 | 4 | 3 | 3 |
| Depreciation | 27 | 25 | 24 | 23 | 20 | 17 | 16 | 16 | 16 | 16 | 15 | 15 | 14 | 13 | 13 | 13 |
| Profit Before Tax | 198 | 287 | 54 | 129 | 18 | 39 | 128 | 49 | 130 | 92 | 104 | 122 | 83 | 110 | 39 | 53 |
| Tax % | 25.0% | 26.0% | 26.0% | 25.0% | 21.0% | 29.0% | 20.0% | 34.0% | 25.0% | 27.0% | 22.0% | 27.0% | 26.0% | 23.0% | 22.0% | 28.0% |
| Net Profit | 148 | 213 | 41 | 97 | 14 | 28 | 102 | 33 | 98 | 68 | 81 | 89 | 62 | 85 | 31 | 38 |
| Exceptional Items | -- | 0 | 0 | 0 | 0 | 0 | 56 | 0 | 21 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | 115.1 | 165.8 | 31.6 | 75.5 | 10.8 | 21.7 | 79.2 | 25.6 | 76.3 | 52.7 | 63.4 | 69.6 | 48.2 | 65.9 | 23.8 | 30.0 |
| Sales Growth (YoY) | 119.1% | 136.6% | 10.6% | 65.3% | -33.4% | -14.8% | 1.3% | -25.6% | 21.2% | -5.4% | 46.1% | 42.2% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -17.3% | 76.4% | -14.4% | 75.4% | -10.7% | -17.6% | 28.0% | -29.3% | 14.3% | -2.0% | -6.0% | 15.2% | -10.8% | 51.3% | -8.5% | -- |
| OP Growth (YoY) | 555.9% | 502.0% | -11.5% | 151.6% | -72.4% | -52.3% | -28.1% | -54.7% | 26.8% | -10.8% | 124.1% | 98.6% | -- | -- | -- | -- |
| OP Growth (QoQ) | -27.4% | 298.7% | -50.6% | 358.8% | -33.3% | -41.4% | 40.3% | -49.6% | 15.0% | -11.6% | -11.7% | 41.2% | -19.2% | 122.2% | -21.7% | -- |
| Profit Growth (YoY) | -- | 665.0% | -29.0% | 195.0% | -83.0% | -59.0% | -30.0% | -63.0% | 33.0% | -20.0% | 166.0% | 132.0% | 521.0% | 288.0% | 136.1% | 89.0% |
| EPS Growth (YoY) | 962.8% | 664.6% | -60.1% | 194.9% | -85.8% | -58.8% | 24.8% | -63.2% | 58.2% | -20.1% | 166.4% | 132.0% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -30.6% | 424.2% | -58.1% | 597.0% | -50.0% | -72.6% | 209.3% | -66.4% | 44.9% | -17.0% | -8.8% | 44.2% | -26.8% | 176.7% | -20.6% | -- |
| OP Margin | 34.7% | 39.6% | 17.5% | 30.4% | 11.6% | 15.6% | 21.9% | 19.9% | 27.9% | 27.8% | 30.8% | 32.8% | 26.7% | 29.5% | 20.1% | 23.5% |
| Net Margin | 23.1% | 27.4% | 9.3% | 18.9% | 4.8% | 8.5% | 25.6% | 10.6% | 22.3% | 17.7% | 20.6% | 21.3% | 17.1% | 20.9% | 11.5% | 12.9% |
| Material Cost % | -- | 34.7% | 43.0% | 35.7% | 38.8% | 38.6% | 41.8% | 37.8% | 40.2% | 35.7% | 36.2% | 36.4% | 40.1% | 42.6% | 39.2% | 37.7% |
| Employee Cost % | -- | 12.7% | 20.2% | 15.6% | 25.1% | 20.2% | 17.4% | 20.3% | 16.6% | 16.2% | 16.7% | 16.5% | 16.5% | 12.2% | 19.2% | 17.8% |
| P/S | 12.60 | 12.22 | 14.30 | 10.73 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 60.06 | 67.93 | 125.70 | 68.52 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 15.94 | 15.26 | 13.90 | 10.16 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Copy of Newspaper Publication
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Malabar India Fund Ltd
Intimation regarding completion of US FDA Inspection
Transcript of the Earnings Call conducted on August 5, 2026
Intimation about Schedule of Analyst / Institutional Investor Meeting on August 12, 2026
Unaudited Financial Results of the Company for the quarter ended June 30, 2026
Unaudited Financial Results of the Company for the quarter ended June 30, 2026
Voting Results, Scrutinizer Report and proceedings of 42nd Annual General Meeting held on August 4, 2026
Voting Results, Scrutinizer Report and proceeding of 42nd Annual General Meeting held on August 4, 2026
Neuland Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve the unaudited financial ....
Intimation of Loss of Share Certificate(s)
Announcement under Regulation 30 (LODR) - Credit Rating
Newspaper Publication regarding dispatch of notice of 42nd Annual General Meeting and Integrated Annual Report for FY 2025-26
Notice of 42nd Annual General Meeting
Notice of 42nd Annual General Meeting and Integrated Annual Report FY 2026
Business Responsibility and Sustainability Report for FY 2025-26
Letter to the Shareholder of the Company in relation to the Notice of 42nd Annual General Meeting and Integrated Annual Report of the Company for FY 2025-26
Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018
Closure of Trading Window
Copy of Newspaper Publication
Intimation about Schedule of Analyst / Institutional Investor Meeting on June 5, 2026
Intimation about Schedule of Analyst / Institutional Investor Meeting on May 28, 2026
Transcript of the Earnings Call conducted on May 12, 2026
Copy of Newspaper Publication
Copy of Newspaper Publication
Audited Financial Results and recommendation of final dividend for financial year 2025-26
Audited Financial Results and recommendation of final dividend for financial year 2025-26
Press Release on the Financial Results of the Company for the quarter and year ended March 31, 2026
Investor Presentation on the Financial Results of the Company for the quarter and year ended March 31, 2026
Recommendation of final dividend for the financial year 2025-26
Error in the Earnings Call Link
Appointment of Dr. Mauricio Futran (DIN: 11699767), as an Additional Director of the Company categorized as Non-Executive Non-Independent
Disclosure under Regulation 30 of SEBI Listing Regulations
The Record Date for the Purpose of Determining the Shareholder Eligible to receive the final dividend for the financial year ended March 31, 2026, has been fixed as July 24, 2026
42nd Annual General Meeting of the Shareholders of the Company is scheduled to be held on Tuesday, August 4, 2026
Correction in Press Release Header
Audio Recording of the Earnings call conducted on May 12, 2026
Q4FY26 Earnings Call Intimation
Newspaper advertisement of Notice for transferring unclaimed dividend and underlying equity shares to IEPF
Neuland Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2026 ,inter alia, to consider and approve the Audited Standalone ....
Copy of Newspaper Publication
Compliance Certificate pursuant to SEBI Exemption Order dated January 3, 2025 for the Financial Year ended March 31, 2026
Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018
Press Release
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 26, 2026 for Davuluri Rao
Closure of Trading Window
Issue of Letter of Confirmation in lieu of Share Certificate(s) lost / misplaced
Intimation of Loss of Share Certificate(s)
Copy of Newspaper Publication
Intimation about Schedule of Analyst / Institutional Investor Meeting between March 10 to 12, 2026
Annual Reports
15Credit Ratings
6Concalls
42Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025May 2025
31 May 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024May 2024
31 May 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022May 2022
31 May 2022Feb 2022
28 Feb 2022Oct 2021
31 Oct 2021Aug 2021
31 Aug 2021May 2021
31 May 2021Feb 2021
28 Feb 2021Nov 2020
30 Nov 2020Jul 2020
31 Jul 2020May 2020
31 May 2020Jan 2020
31 Jan 2020Nov 2019
30 Nov 2019Aug 2019
31 Aug 2019Feb 2019
28 Feb 2019Nov 2018
30 Nov 2018Oct 2018
31 Oct 2018May 2018
31 May 2018Jan 2018
31 Jan 2018Nov 2017
30 Nov 2017Sep 2017
30 Sept 2017May 2017
31 May 2017Feb 2017
28 Feb 2017Nov 2016
30 Nov 2016Aug 2016
31 Aug 2016May 2016
31 May 2016Held by ETFs
16 ETFs hold NEULANDLAB · sorted by weight
Held by Mutual Funds
71 schemes hold NEULANDLAB · sorted by weight